Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: MNKD

MannKind Corporation

Healthcare | Biotechnology

No licensed closing price on file for MNKD. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.13

MannKind Corporation (NASDAQ: MNKD) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 12:41 UTC.

What MannKind Corporation does

MannKind Corporation is a biopharmaceutical company that develops and commercializes treatments for cardiometabolic and orphan lung diseases. The company's cardiometabolic business includes three commercial products: Afrezza, an inhaled insulin; Furoscix, a subcutaneous diuretic; and V-Go, a wearable insulin delivery device. In the United States, the company handles commercialization directly, while internationally it partners with regional companies such as Cipla in India.

Summarized from MannKind Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.13

Revenue, margins & earnings

FY2021: net loss $81M on revenue $75M$75MFY2021FY2022: net loss $87M on revenue $100M$100MFY2022FY2023: net loss $12M on revenue $199M$199MFY2023FY2024 Net income: $28MFY2024 Taxes & interest: $45MFY2024 Operating costs: $213M$286MFY2024FY2025 Net income: $6MFY2025 Taxes & interest: $33MFY2025 Operating costs: $310M$349MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-28
  • 2026-09-28DirectorSale-39,051$128.5K
  • 2026-09-14DirectorSale-33,558$127.9K
  • 2026-08-10DirectorSale-39,051$158.5K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does MannKind Corporation do?

MannKind Corporation is a biopharmaceutical company that develops and commercializes treatments for cardiometabolic and orphan lung diseases.

When did MNKD last file with the SEC?

MannKind Corporation's most recent SEC filing on record is a 8-K filed 2026-06-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 12:41 UTC. This page is also available as JSON at /api/data?ticker=MNKD and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MNKD and 5,000+ tickers.

Create a free account — keep MNKD
For your agent
GET /api/data?ticker=MNKD

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt